

Section 32
Adolescent and Young Adult Cancer by Site
Incidence, Survival and Mortality

Tumors affecting adolescents and young adults often differ from those affecting pediatric and older adult populations¹. For this reason, a classification scheme has been proposed for tumors diagnosed in adolescents and young adults². This classification scheme was updated based on site and histology codes of the International Classification of Diseases for Oncology, Third Edition³. Effective 2001, all cases reported to SEER were required to have an ICD-O-3 histology and behavior code and all previous cases were converted to ICD-O-3⁴. In addition, although benign brain tumors have also been reported to SEER since 2004, not enough time has elapsed to present rates and trend data for these tumors. These site / histology groupings, however, are not comparable with the groupings of ICD-10 for mortality. Therefore, for incidence and mortality comparisons, the SEER site recode as described in the appendix was used⁵. In this chapter, the incidence of malignant cancers in adolescent and young adults, 15 to 39 years of age, are presented based on the 2 different classification schemes described above.

REFERENCES:

1. The distinctive biology of cancer in adolescents and young adults. Bleyer A, Barr R, Hayes-Lattin B, et al. *Nat Rev Cancer*. 2008; 8: 288-98.
2. Barr RD, Holowaty EJ, Birch JM. Classification schemes for tumors diagnosed in adolescents and young adults. *Cancer* 2006; 106: 1425-1430.
3. International Classification of Diseases for Oncology, Third Edition Edited by A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, D.M. Parkin and S. Whelan. World Health Organization. Geneva, Switzerland, 2000. 240 pp.
4. National Cancer Institute SEER Conversion Programs.
Worldwide web: (<http://seer.cancer.gov/tools/conversion/>) Accessed May 28, 2008.
5. National Cancer Institute Cancer Statistics Review 1975-2010. Appendix.
Worldwide web: (http://seer.cancer.gov/csr/1975_2010/results_merged/topic_siterecode.pdf.)
Released April 15, 2013.

Table 32.1

Age-Adjusted SEER Incidence^a, by Age Group and Sex
 By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
 All Races, 2007-2011

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
All Sites Combined	17.0	15.1	53.2	85.6	1177.9	877.8
1. LEUKEMIAS	5.6	4.9	3.6	2.8	32.9	18.8
1.1 Acute lymphoid leukemia	4.5	3.9	1.2	0.8	1.2	0.9
1.2 Acute myeloid leukemia	0.8	0.8	1.3	1.3	10.0	6.5
1.3 Chronic myeloid leukemia	0.1	0.1	0.8	0.5	4.4	2.4
1.4 Other and unspecified leukemias	0.2	0.1	0.4	0.3	17.3	8.9
2. LYMPHOMAS	2.0	1.1	8.6	6.8	54.6	37.4
2.1 Non-Hodgkin Lymphoma	1.3	0.6	4.9	3.3	50.8	34.9
2.2 Hodgkin Lymphoma	0.7	0.5	3.7	3.6	3.8	2.5
3. CNS, INTRACRANIAL, INTRASPINAL	3.3	3.1	3.2	2.4	13.3	8.9
3.1 Astrocytoma	1.6	1.7	1.8	1.3	10.3	6.6
3.1.1 Specified low-grade astrocytic tumors	1.1	1.2	0.5	0.4	0.4	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.3	0.2	0.9	0.5	9.3	5.9
3.1.3 Astrocytoma, NOS	0.2	0.2	0.4	0.3	0.6	0.4
3.2 Other glioma	0.6	0.6	0.9	0.7	1.5	1.1
3.3 Ependymoma	0.3	0.3	0.2	0.2	0.3	0.3
3.4 Medulloblastoma and other PNET	0.8	0.5	0.2	0.2	0.1	0.1
3.4.1 Medulloblastoma	0.5	0.3	0.1	0.1	0.0	-
3.4.2 Supratentorial PNET	0.3	0.2	0.1	0.1	0.1	0.1
3.5 Other specified intracranial and intraspinal neoplasms	0.1	0.1	0.1	0.1	0.2	0.3
3.6 Unspecified intracranial and intraspinal neoplasms	0.0	-	0.1	0.0	0.8	0.6
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	0.9	0.8	1.1	0.8	1.5	1.0
4.1 Osteosarcoma	0.4	0.4	0.4	0.3	0.3	0.2
4.2 Chondrosarcoma	0.1	-	0.2	0.2	0.7	0.5
4.3 Ewing tumor	0.4	0.3	0.3	0.2	0.1	0.1
4.4 Other specified and unspecified bone tumors	0.0	0.0	0.1	0.1	0.4	0.3
5. SOFT TISSUE SARCOMAS	1.1	0.9	3.3	2.4	12.7	9.0
5.1 Fibromatous neoplasms	0.1	0.1	0.7	0.8	2.9	1.7
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	0.1	0.2	0.2
5.3 Other specified soft tissue sarcoma	0.3	0.3	2.4	1.5	9.5	7.2
5.3.1 Specified soft tissue sarcoma	0.2	0.2	2.0	1.2	7.0	5.4
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.2	0.2	1.1	1.1	5.4	5.2
5.3.1.2 Kaposi sarcoma	-	-	1.0	0.0	1.6	0.2
5.3.2 Unspecified soft tissue sarcoma	0.1	0.1	0.4	0.3	2.5	1.8
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	0.6	0.6	10.9	1.1	4.1	0.2
6.1 Germ cell and trophoblastic neoplasms of gonads	0.2	0.3	10.4	0.7	3.9	0.1
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.3	0.3	0.5	0.3	0.1	0.1
6.2.1 Intracranial sites	0.2	0.1	0.2	0.0	-	-
6.2.2 Other nongonadal sites	0.1	0.2	0.3	0.3	0.1	0.1

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.1 - continued

Age-Adjusted SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
All Races, 2007-2011

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	0.2	0.2	5.4	8.9	66.0	35.3
7.1 Melanoma	0.2	0.2	5.3	8.8	61.9	33.3
7.2 Skin carcinomas	-	-	0.1	0.1	4.1	2.0
8. CARCINOMAS (excluding skin)	0.4	0.8	16.1	58.7	930.5	719.7
8.1 Thyroid carcinoma	0.1	0.4	3.3	16.7	12.0	30.3
8.2 Other carcinoma of head and neck	0.1	0.1	1.9	1.5	51.6	16.5
8.2.1 Nasopharyngeal carcinoma	0.0	-	0.3	0.2	1.8	0.7
8.2.2 Other sites in lip, oral cavity and pharynx	0.1	0.1	1.2	1.1	34.2	12.2
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	0.3	0.2	15.6	3.6
8.3 Carcinoma of trachea, bronchus, and lung	-	-	1.0	1.1	154.1	109.1
8.4 Carcinoma of breast	-	-	0.1	20.4	2.8	268.7
8.5 Carcinoma of genitourinary tract	0.0	0.1	3.5	13.2	470.0	135.8
8.5.1 Carcinoma of kidney	-	0.0	2.2	1.6	43.2	20.8
8.5.2 Carcinoma of bladder	-	-	0.8	0.3	82.2	19.7
8.5.3 Carcinoma of gonads	-	-	0.0	1.8	0.0	23.2
8.5.4 Carcinoma of cervix and uterus	-	-	-	9.1	-	61.2
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	0.4	0.4	344.6	10.9
8.6 Carcinoma of gastrointestinal tract	0.1	0.1	5.9	5.3	222.0	143.3
8.6.1 Carcinoma of colon and rectum	-	-	3.8	3.5	115.2	87.9
8.6.2 Carcinoma of stomach	-	-	0.7	0.7	21.6	10.4
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.1	-	0.5	0.3	26.7	8.5
8.6.4 Carcinoma of pancreas	-	-	0.4	0.4	28.2	21.5
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	0.5	0.3	30.3	14.9
8.7 Carcinoma of other and ill-defined sites, NOS	0.0	0.0	0.5	0.6	18.0	16.0
8.7.1 Adrenocortical carcinoma	-	-	0.0	0.1	0.2	0.3
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.4	0.5	17.8	15.7
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	3.0	2.7	0.8	1.1	26.2	20.9
9.1 Other pediatric and embryonal tumors, NOS	2.8	2.6	0.1	0.1	0.2	0.1
9.1.1 Wilms tumor	0.7	0.8	-	0.0	-	0.0
9.1.2 Neuroblastoma	1.1	1.0	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	1.0	0.8	0.1	0.1	0.2	0.1
9.2 Other specified neoplasms, NOS	0.1	0.1	0.7	1.1	26.0	20.7
9.2.1 Paraganglioma and glomus tumors	-	-	0.1	0.0	0.1	0.1
9.2.2 Other specified gonadal tumors	-	-	0.0	0.2	0.0	0.4
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	0.1	0.1	0.4	0.3	19.0	11.9
9.2.4 Other specified neoplasms, NOS	-	-	0.2	0.6	6.8	8.3
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.3	0.5	36.4	26.4

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.2

Age-Adjusted SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
White, 2007-2011

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
All Sites Combined	18.0	16.1	57.3	90.8	1180.2	903.2
1. LEUKEMIAS	6.1	5.4	3.8	3.0	34.4	19.6
1.1 Acute lymphoid leukemia	4.9	4.4	1.3	0.9	1.3	1.0
1.2 Acute myeloid leukemia	0.8	0.8	1.3	1.3	10.4	6.7
1.3 Chronic myeloid leukemia	0.1	0.1	0.7	0.4	4.5	2.5
1.4 Other and unspecified leukemias	0.2	0.1	0.4	0.3	18.2	9.5
2. LYMPHOMAS	2.0	1.1	8.8	7.1	57.2	39.6
2.1 Non-Hodgkin Lymphoma	1.3	0.6	4.8	3.2	53.2	36.9
2.2 Hodgkin Lymphoma	0.7	0.5	4.0	3.9	4.0	2.6
3. CNS, INTRACRANIAL, INTRASPINAL	3.6	3.4	3.6	2.6	14.6	9.9
3.1 Astrocytoma	1.7	1.8	1.9	1.4	11.5	7.4
3.1.1 Specified low-grade astrocytic tumors	1.2	1.4	0.5	0.4	0.4	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.3	0.2	1.0	0.6	10.4	6.6
3.1.3 Astrocytoma, NOS	0.2	0.2	0.4	0.3	0.7	0.5
3.2 Other glioma	0.6	0.6	1.1	0.8	1.6	1.2
3.3 Ependymoma	0.3	0.3	0.2	0.2	0.4	0.3
3.4 Medulloblastoma and other PNET	0.9	0.5	0.3	0.2	0.1	0.1
3.4.1 Medulloblastoma	0.5	0.3	0.2	0.1	0.0	-
3.4.2 Supratentorial PNET	0.3	0.2	0.1	0.1	0.1	0.1
3.5 Other specified intracranial and intraspinal neoplasms	0.1	0.1	0.1	0.1	0.2	0.3
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	0.1	-	0.8	0.7
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	1.0	0.8	1.2	0.8	1.5	1.1
4.1 Osteosarcoma	0.5	0.4	0.4	0.3	0.3	0.2
4.2 Chondrosarcoma	0.1	-	0.2	0.2	0.7	0.5
4.3 Ewing tumor	0.5	0.4	0.4	0.3	0.1	0.1
4.4 Other specified and unspecified bone tumors	-	-	0.1	0.1	0.4	0.3
5. SOFT TISSUE SARCOMAS	1.1	0.9	2.9	2.2	13.0	8.8
5.1 Fibromatous neoplasms	0.2	0.1	0.6	0.7	3.0	1.6
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	0.1	0.2	0.1
5.3 Other specified soft tissue sarcoma	0.3	0.3	2.1	1.4	9.7	7.0
5.3.1 Specified soft tissue sarcoma	0.2	0.2	1.8	1.1	7.1	5.3
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.2	0.2	1.1	1.1	5.6	5.1
5.3.1.2 Kaposi sarcoma	-	-	0.7	-	1.5	0.2
5.3.2 Unspecified soft tissue sarcoma	0.1	0.1	0.4	0.3	2.6	1.7
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	0.6	0.6	13.1	1.1	4.7	0.2
6.1 Germ cell and trophoblastic neoplasms of gonads	0.3	0.3	12.6	0.8	4.6	0.1
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.3	0.2	0.6	0.3	0.2	0.1
6.2.1 Intracranial sites	0.2	0.1	0.2	-	-	-
6.2.2 Other nongonadal sites	0.1	0.2	0.4	0.3	0.1	0.1

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.2 - continued

Age-Adjusted SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
White, 2007-2011

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	0.2	0.2	6.6	11.2	76.3	41.6
7.1 Melanoma	0.2	0.2	6.5	11.1	71.8	39.4
7.2 Skin carcinomas	-	-	0.1	0.1	4.5	2.1
8. CARCINOMAS (excluding skin)	0.4	0.8	16.2	61.1	917.4	736.5
8.1 Thyroid carcinoma	0.1	0.5	3.6	18.5	12.8	31.7
8.2 Other carcinoma of head and neck	0.1	0.1	1.8	1.4	53.1	17.0
8.2.1 Nasopharyngeal carcinoma	-	-	0.2	0.1	1.2	0.5
8.2.2 Other sites in lip, oral cavity and pharynx	0.1	0.1	1.3	1.2	36.3	12.8
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	0.3	0.2	15.7	3.7
8.3 Carcinoma of trachea, bronchus, and lung	-	-	1.0	1.1	154.5	114.7
8.4 Carcinoma of breast	-	-	0.1	20.2	2.8	276.9
8.5 Carcinoma of genitourinary tract	-	0.1	3.5	14.2	461.0	141.9
8.5.1 Carcinoma of kidney	-	-	2.2	1.7	44.1	21.4
8.5.2 Carcinoma of bladder	-	-	0.9	0.4	89.4	21.3
8.5.3 Carcinoma of gonads	-	-	0.1	1.9	0.0	24.7
8.5.4 Carcinoma of cervix and uterus	-	-	-	9.7	-	63.0
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	0.4	0.5	327.4	11.5
8.6 Carcinoma of gastrointestinal tract	0.1	0.1	5.8	5.2	214.9	138.1
8.6.1 Carcinoma of colon and rectum	-	-	3.8	3.6	113.2	86.3
8.6.2 Carcinoma of stomach	-	-	0.7	0.6	19.4	8.8
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.1	-	0.3	0.3	23.4	7.3
8.6.4 Carcinoma of pancreas	-	-	0.4	0.4	28.2	21.2
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	0.6	0.3	30.7	14.5
8.7 Carcinoma of other and ill-defined sites, NOS	-	0.1	0.5	0.5	18.2	16.2
8.7.1 Adrenocortical carcinoma	-	-	0.0	0.1	0.2	0.3
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.4	0.5	18.0	15.9
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	3.1	2.8	0.8	1.1	25.4	19.1
9.1 Other pediatric and embryonal tumors, NOS	2.9	2.7	0.1	0.1	0.2	0.1
9.1.1 Wilms tumor	0.7	0.9	-	-	-	0.0
9.1.2 Neuroblastoma	1.2	1.0	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	1.0	0.9	0.1	0.0	0.2	0.1
9.2 Other specified neoplasms, NOS	0.1	0.1	0.7	1.0	25.2	19.0
9.2.1 Paraganglioma and glomus tumors	-	-	0.1	0.0	0.1	0.1
9.2.2 Other specified gonadal tumors	-	-	-	0.1	0.0	0.4
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	0.1	0.1	0.4	0.2	18.1	10.7
9.2.4 Other specified neoplasms, NOS	-	-	0.2	0.6	7.0	7.8
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.3	0.5	35.6	26.9

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.3

Age-Adjusted SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
Black, 2007-2011

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
All Sites Combined	13.3	12.0	39.9	70.0	1356.8	863.1
1. LEUKEMIAS	3.7	2.8	2.9	2.2	25.5	15.3
1.1 Acute lymphoid leukemia	2.7	1.8	0.7	0.3	0.8	0.7
1.2 Acute myeloid leukemia	0.7	0.8	1.0	1.1	8.0	5.7
1.3 Chronic myeloid leukemia	-	-	0.8	0.6	3.8	2.5
1.4 Other and unspecified leukemias	-	-	0.4	0.2	12.9	6.3
2. LYMPHOMAS	2.0	1.2	9.8	7.0	38.6	26.7
2.1 Non-Hodgkin Lymphoma	1.3	0.7	6.2	3.8	34.7	24.3
2.2 Hodgkin Lymphoma	0.7	0.5	3.7	3.2	3.8	2.4
3. CNS, INTRACRANIAL, INTRASPINAL	2.4	2.6	1.9	1.8	8.2	5.7
3.1 Astrocytoma	1.0	1.3	1.0	0.9	6.0	3.9
3.1.1 Specified low-grade astrocytic tumors	0.7	0.9	0.2	0.4	0.2	0.2
3.1.2 Glioblastoma and anaplastic astrocytoma	0.2	-	0.5	0.4	5.5	3.4
3.1.3 Astrocytoma, NOS	-	-	0.3	0.2	0.3	0.3
3.2 Other glioma	0.5	0.5	0.4	0.5	0.9	0.6
3.3 Ependymoma	0.2	-	0.2	0.2	0.2	0.2
3.4 Medulloblastoma and other PNET	0.4	0.4	-	0.2	-	-
3.4.1 Medulloblastoma	-	0.3	-	-	-	-
3.4.2 Supratentorial PNET	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	0.4	0.3
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	0.7	0.6
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	0.6	0.5	0.9	0.7	1.1	1.0
4.1 Osteosarcoma	0.4	0.3	0.4	0.4	0.3	0.5
4.2 Chondrosarcoma	-	-	0.3	-	0.5	0.3
4.3 Ewing tumor	-	-	-	-	-	-
4.4 Other specified and unspecified bone tumors	-	-	-	-	0.3	0.2
5. SOFT TISSUE SARCOMAS	1.3	1.1	5.9	3.3	11.0	11.4
5.1 Fibromatous neoplasms	-	-	1.1	1.1	2.2	2.0
5.2 Rhabdomyosarcoma	0.9	0.4	0.2	0.2	-	0.3
5.3 Other specified soft tissue sarcoma	0.3	0.5	4.5	2.0	8.7	9.1
5.3.1 Specified soft tissue sarcoma	-	0.4	4.0	1.7	6.7	7.0
5.3.1.1 Specified (excluding Kaposi sarcoma)	-	0.4	1.1	1.5	4.2	6.7
5.3.1.2 Kaposi sarcoma	-	-	2.9	-	2.5	0.3
5.3.2 Unspecified soft tissue sarcoma	-	-	0.5	0.4	2.0	2.2
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	-	0.7	2.3	1.0	1.3	0.3
6.1 Germ cell and trophoblastic neoplasms of gonads	-	0.4	2.0	0.5	1.1	-
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	-	0.3	0.2	0.5	0.2	0.2
6.2.1 Intracranial sites	-	-	-	-	-	-
6.2.2 Other nongonadal sites	-	-	-	0.4	0.2	0.2

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.3 - continued

Age-Adjusted SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
Black, 2007-2011

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	-	-	0.3	0.4	3.5	3.2
7.1 Melanoma	-	-	0.2	0.3	2.6	2.4
7.2 Skin carcinomas	-	-	-	-	1.0	0.8
8. CARCINOMAS (excluding skin)	0.4	0.4	14.6	51.5	1172.7	730.7
8.1 Thyroid carcinoma	-	-	1.2	7.5	6.4	19.6
8.2 Other carcinoma of head and neck	-	-	1.5	1.4	54.8	15.3
8.2.1 Nasopharyngeal carcinoma	-	-	0.3	0.2	2.1	0.5
8.2.2 Other sites in lip, oral cavity and pharynx	-	-	0.8	1.1	30.2	10.2
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	0.4	-	22.5	4.7
8.3 Carcinoma of trachea, bronchus, and lung	-	-	1.1	0.9	198.5	110.5
8.4 Carcinoma of breast	-	-	-	24.4	3.9	260.5
8.5 Carcinoma of genitourinary tract	-	-	4.0	10.5	611.1	124.2
8.5.1 Carcinoma of kidney	-	-	2.7	1.7	52.1	25.4
8.5.2 Carcinoma of bladder	-	-	0.5	-	47.6	15.5
8.5.3 Carcinoma of gonads	-	-	-	1.2	-	17.4
8.5.4 Carcinoma of cervix and uterus	-	-	-	7.0	-	57.2
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	0.9	0.5	511.4	8.8
8.6 Carcinoma of gastrointestinal tract	-	-	6.0	5.9	277.8	182.7
8.6.1 Carcinoma of colon and rectum	-	-	3.9	3.7	142.4	107.6
8.6.2 Carcinoma of stomach	-	-	0.7	0.8	31.5	16.3
8.6.3 Carcinoma of liver and intrahepatic bile ducts	-	-	0.7	0.3	33.9	9.7
8.6.4 Carcinoma of pancreas	-	-	0.4	0.7	34.7	28.4
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	0.4	0.5	35.4	20.7
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	0.6	0.8	20.2	17.8
8.7.1 Adrenocortical carcinoma	-	-	-	-	0.3	0.2
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.6	0.7	19.9	17.6
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	2.6	2.7	1.0	1.7	41.7	39.2
9.1 Other pediatric and embryonal tumors, NOS	2.5	2.7	-	-	-	0.2
9.1.1 Wilms tumor	0.8	1.0	-	-	-	-
9.1.2 Neuroblastoma	1.0	1.0	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	0.8	0.7	-	-	-	-
9.2 Other specified neoplasms, NOS	-	-	0.9	1.6	41.5	39.1
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	0.2	0.2
9.2.2 Other specified gonadal tumors	-	-	-	0.4	-	0.7
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	0.6	0.5	34.7	24.7
9.2.4 Other specified neoplasms, NOS	-	-	0.2	0.7	6.6	13.4
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.4	0.6	53.1	29.5

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.4
Age-Specific SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
All Races, 2007-2011

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
All Sites Combined	22.6	20.6	34.6	37.1	48.7	66.0	65.1	111.1	88.9	176.8
1. LEUKEMIAS	3.6	2.7	3.0	2.2	3.3	2.4	3.6	3.0	4.5	3.6
1.1 Acute lymphoid leukemia	2.3	1.3	1.3	0.7	0.9	0.6	0.7	0.6	0.7	0.6
1.2 Acute myeloid leukemia	0.9	1.1	0.9	1.0	1.3	1.2	1.4	1.5	1.7	1.7
1.3 Chronic myeloid leukemia	0.3	0.2	0.5	0.4	0.8	0.5	1.0	0.5	1.2	0.7
1.4 Other and unspecified leukemias	0.1	-	0.2	-	0.2	0.2	0.4	0.3	0.9	0.6
2. LYMPHOMAS	5.2	4.5	7.4	6.5	8.2	7.1	9.8	7.4	11.7	8.5
2.1 Non-Hodgkin Lymphoma	2.2	1.2	3.1	1.9	4.1	2.9	5.9	3.9	8.4	5.9
2.2 Hodgkin Lymphoma	3.0	3.3	4.3	4.6	4.1	4.1	3.9	3.5	3.3	2.6
3. CNS, INTRACRANIAL, INTRASPINAL	2.2	1.9	2.3	2.1	3.1	2.4	4.0	2.8	4.4	2.9
3.1 Astrocytoma	1.2	1.1	1.2	1.1	1.6	1.1	2.0	1.4	2.6	1.5
3.1.1 Specified low-grade astrocytic tumors	0.7	0.7	0.4	0.5	0.4	0.3	0.4	0.4	0.4	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.4	0.2	0.4	0.3	0.8	0.6	1.1	0.6	1.7	0.8
3.1.3 Astrocytoma, NOS	0.2	0.2	0.3	0.2	0.4	0.3	0.5	0.4	0.5	0.4
3.2 Other glioma	0.4	0.3	0.6	0.5	1.0	0.8	1.4	1.0	1.2	0.9
3.3 Ependymoma	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.2
3.4 Medulloblastoma and other PNET	0.3	0.2	0.3	0.2	0.2	0.1	0.2	-	0.2	0.1
3.4.1 Medulloblastoma	0.2	0.1	0.1	0.2	0.1	-	-	-	0.1	-
3.4.2 Supratentorial PNET	0.1	-	0.1	-	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	2.0	1.1	1.2	0.9	0.8	0.8	0.7	0.5	0.7	0.6
4.1 Osteosarcoma	1.0	0.6	0.5	0.3	0.2	0.3	0.1	0.1	0.2	0.2
4.2 Chondrosarcoma	0.2	-	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.2
4.3 Ewing tumor	0.7	0.4	0.5	0.3	0.2	0.2	0.2	0.1	0.1	0.1
4.4 Other specified and unspecified bone tumors	-	-	-	0.1	0.1	-	0.1	0.1	0.1	-
5. SOFT TISSUE SARCOMAS	1.4	1.3	2.0	1.8	3.3	2.1	4.3	3.0	5.1	3.4
5.1 Fibromatous neoplasms	0.2	0.3	0.4	0.5	0.7	0.7	0.9	1.1	1.2	1.1
5.2 Rhabdomyosarcoma	0.4	0.3	0.2	0.1	0.1	-	-	-	-	-
5.3 Other specified soft tissue sarcoma	0.7	0.7	1.5	1.1	2.4	1.3	3.3	1.8	3.8	2.3
5.3.1 Specified soft tissue sarcoma	0.5	0.5	1.2	0.8	2.0	1.0	2.9	1.5	3.3	1.9
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.5	0.5	0.8	0.8	0.9	1.0	1.4	1.4	1.7	1.8
5.3.1.2 Kaposi sarcoma	-	-	0.4	-	1.1	-	1.5	-	1.7	-
5.3.2 Unspecified soft tissue sarcoma	0.2	0.2	0.4	0.3	0.4	0.2	0.4	0.3	0.5	0.4
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	4.6	1.1	11.0	1.3	14.8	1.2	13.7	1.0	10.8	0.7
6.1 Germ cell and trophoblastic neoplasms of gonads	3.8	0.9	10.4	1.0	14.2	0.8	13.4	0.6	10.5	0.4
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.7	0.2	0.6	0.4	0.6	0.4	0.4	0.4	0.3	0.4
6.2.1 Intracranial sites	0.5	-	0.2	-	0.2	-	-	-	-	-
6.2.2 Other nongonadal sites	0.2	0.1	0.4	0.3	0.4	0.4	0.3	0.4	0.3	0.4

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.4 - continued
 Age-Specific SEER Incidence^a, by Age Group and Sex
 By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
 All Races, 2007-2011

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	1.0	1.4	2.2	5.4	4.4	9.4	7.6	11.6	10.7	15.8
7.1 Melanoma	0.9	1.4	2.2	5.4	4.3	9.3	7.4	11.5	10.6	15.6
7.2 Skin carcinomas	-	-	-	-	-	-	0.1	-	0.2	0.2
8. CARCINOMAS (excluding skin)	2.4	6.1	5.0	16.2	10.1	39.4	20.1	79.7	38.7	137.8
8.1 Thyroid carcinoma	0.9	4.1	1.5	9.3	2.9	16.2	4.6	23.4	6.3	28.4
8.2 Other carcinoma of head and neck	0.5	0.5	0.7	0.8	1.0	1.1	1.9	1.9	4.6	2.9
8.2.1 Nasopharyngeal carcinoma	0.2	-	0.2	-	0.2	0.1	0.3	0.2	0.8	0.4
8.2.2 Other sites in lip, oral cavity and pharynx	0.2	0.4	0.4	0.6	0.7	0.9	1.4	1.5	3.0	2.2
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	-	-	0.1	0.1	0.2	0.2	0.8	0.3
8.3 Carcinoma of trachea, bronchus, and lung	0.1	0.1	0.4	0.3	0.5	0.6	1.2	1.2	2.7	2.8
8.4 Carcinoma of breast	-	-	-	1.4	-	8.3	-	26.3	0.2	58.8
8.5 Carcinoma of genitourinary tract	0.3	0.6	0.7	2.8	1.8	9.5	4.3	19.4	9.2	30.6
8.5.1 Carcinoma of kidney	0.1	0.2	0.4	0.5	1.1	1.2	2.8	2.2	5.9	3.7
8.5.2 Carcinoma of bladder	-	-	0.3	-	0.6	0.2	1.1	0.4	1.8	0.8
8.5.3 Carcinoma of gonads	-	0.3	-	0.6	-	1.3	-	2.4	-	4.1
8.5.4 Carcinoma of cervix and uterus	-	0.1	-	1.5	-	6.6	-	13.8	-	21.0
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	-	-	-	0.2	0.3	0.7	1.4	1.1
8.6 Carcinoma of gastrointestinal tract	0.6	0.6	1.6	1.4	3.4	3.2	7.4	6.7	14.7	13.0
8.6.1 Carcinoma of colon and rectum	0.3	0.3	1.1	0.8	2.3	2.2	5.1	4.4	9.3	9.0
8.6.2 Carcinoma of stomach	-	-	0.2	0.2	0.3	0.4	0.9	1.1	1.8	1.5
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.2	0.1	0.2	0.1	0.3	0.2	0.5	0.3	1.1	0.6
8.6.4 Carcinoma of pancreas	-	-	-	0.2	0.2	0.2	0.4	0.6	1.1	0.9
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	-	-	0.3	0.2	0.5	0.3	1.5	1.0
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	0.2	0.3	0.4	0.5	0.7	0.7	1.1	1.3
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	0.1
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.1	0.3	0.3	0.4	0.6	0.6	1.0	1.2
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	0.3	0.4	0.3	0.5	0.6	0.8	1.0	1.4	1.6	2.4
9.1 Other pediatric and embryonal tumors, NOS	0.1	0.1	-	-	-	-	-	0.1	-	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	-	-	-	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.2 Other specified neoplasms, NOS	0.2	0.3	0.2	0.4	0.5	0.8	0.9	1.3	1.6	2.3
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	-	-	0.1	-	0.2	-	0.3
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	0.1	-	0.3	0.1	0.5	0.3	1.0	0.7
9.2.4 Other specified neoplasms, NOS ^c	-	0.1	-	0.2	0.2	0.5	0.3	0.8	0.4	1.3
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.1	0.3	0.2	0.4	0.4	0.7	0.6	1.1

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.5
Age-Specific SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
White, 2007-2011

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
All Sites Combined	24.9	22.5	38.8	40.6	53.4	71.1	69.6	118.0	93.9	184.9
1. LEUKEMIAS	4.0	3.0	3.2	2.3	3.5	2.6	3.7	3.0	4.5	3.8
1.1 Acute lymphoid leukemia	2.6	1.5	1.5	0.8	1.0	0.8	0.9	0.7	0.8	0.7
1.2 Acute myeloid leukemia	1.0	1.1	1.0	1.1	1.4	1.2	1.5	1.5	1.7	1.8
1.3 Chronic myeloid leukemia	0.3	0.2	0.5	0.4	0.9	0.4	0.9	0.5	1.1	0.7
1.4 Other and unspecified leukemias	0.2	-	0.2	-	0.2	0.2	0.4	0.3	0.9	0.6
2. LYMPHOMAS	5.7	5.0	7.8	6.9	8.3	7.4	9.8	7.6	12.1	8.6
2.1 Non-Hodgkin Lymphoma	2.3	1.3	3.2	1.8	4.0	2.8	5.5	3.8	8.6	5.8
2.2 Hodgkin Lymphoma	3.4	3.7	4.6	5.1	4.3	4.6	4.2	3.8	3.5	2.8
3. CNS, INTRACRANIAL, INTRASPINAL	2.3	2.0	2.6	2.3	3.6	2.7	4.3	3.2	5.0	3.1
3.1 Astrocytoma	1.3	1.1	1.3	1.2	1.9	1.2	2.2	1.6	3.0	1.6
3.1.1 Specified low-grade astrocytic tumors	0.7	0.7	0.5	0.6	0.5	0.3	0.5	0.4	0.5	0.2
3.1.2 Glioblastoma and anaplastic astrocytoma	0.4	0.2	0.4	0.4	1.0	0.6	1.2	0.7	2.0	0.9
3.1.3 Astrocytoma, NOS	0.2	0.2	0.4	0.3	0.4	0.3	0.5	0.4	0.5	0.5
3.2 Other glioma	0.5	0.4	0.6	0.6	1.2	0.9	1.6	1.2	1.4	1.0
3.3 Ependymoma	0.2	-	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.2
3.4 Medulloblastoma and other PNET	0.3	0.2	0.3	0.2	0.2	0.2	0.2	-	0.2	-
3.4.1 Medulloblastoma	0.2	0.1	0.2	0.2	0.2	-	-	-	-	-
3.4.2 Supratentorial PNET	0.1	-	0.2	-	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	2.1	1.2	1.3	0.8	0.9	0.9	0.7	0.6	0.7	0.7
4.1 Osteosarcoma	1.0	0.6	0.5	0.3	0.2	0.3	0.2	-	0.2	0.2
4.2 Chondrosarcoma	0.1	-	0.2	-	0.3	0.2	0.3	0.2	0.3	0.2
4.3 Ewing tumor	0.8	0.4	0.6	0.3	0.3	0.2	0.2	0.2	-	0.2
4.4 Other specified and unspecified bone tumors	-	-	-	-	0.2	-	-	-	-	-
5. SOFT TISSUE SARCOMAS	1.4	1.4	1.7	1.7	2.9	2.1	3.8	2.7	4.5	3.3
5.1 Fibromatous neoplasms	0.2	0.3	0.3	0.5	0.7	0.7	0.8	1.1	0.9	1.0
5.2 Rhabdomyosarcoma	0.4	0.2	0.2	-	0.1	-	-	-	-	-
5.3 Other specified soft tissue sarcoma	0.7	0.8	1.3	1.1	2.1	1.3	2.9	1.5	3.5	2.2
5.3.1 Specified soft tissue sarcoma	0.6	0.6	0.9	0.9	1.6	1.0	2.5	1.2	3.0	1.8
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.6	0.6	0.7	0.8	0.9	1.0	1.4	1.2	1.7	1.8
5.3.1.2 Kaposi sarcoma	-	-	0.2	-	0.7	-	1.2	-	1.3	-
5.3.2 Unspecified soft tissue sarcoma	0.1	0.2	0.4	0.3	0.4	0.3	0.4	0.3	0.5	0.4
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	5.6	1.1	13.5	1.4	17.7	1.2	16.5	0.9	13.0	0.7
6.1 Germ cell and trophoblastic neoplasms of gonads	4.8	1.0	12.8	1.0	17.1	0.9	16.1	0.5	12.6	0.4
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.7	-	0.7	0.3	0.7	0.4	0.4	0.4	0.3	0.3
6.2.1 Intracranial sites	0.5	-	0.2	-	0.2	-	-	-	-	-
6.2.2 Other nongonadal sites	0.3	-	0.4	0.3	0.5	0.4	0.3	0.4	0.3	0.3

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.5 - continued
 Age-Specific SEER Incidence^a, by Age Group and Sex
 By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
 White, 2007-2011

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	1.2	1.9	2.8	6.7	5.3	11.7	9.1	14.6	13.2	19.8
7.1 Melanoma	1.1	1.8	2.8	6.7	5.3	11.6	9.0	14.5	13.0	19.6
7.2 Skin carcinomas	-	-	-	-	-	-	-	-	0.2	0.2
8. CARCINOMAS (excluding skin)	2.3	6.7	5.4	17.7	10.3	41.5	20.3	83.4	38.6	141.6
8.1 Thyroid carcinoma	1.0	4.7	1.7	10.9	3.2	18.3	4.9	26.2	6.9	30.6
8.2 Other carcinoma of head and neck	0.4	0.5	0.7	0.7	0.9	1.1	1.9	1.8	4.5	2.7
8.2.1 Nasopharyngeal carcinoma	0.1	-	0.2	-	-	-	0.2	-	0.4	-
8.2.2 Other sites in lip, oral cavity and pharynx	0.2	0.4	0.5	0.6	0.7	0.9	1.5	1.5	3.2	2.1
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	-	-	-	-	0.2	0.2	0.9	0.4
8.3 Carcinoma of trachea, bronchus, and lung	-	0.1	0.4	0.4	0.5	0.6	1.1	1.2	2.7	3.0
8.4 Carcinoma of breast	-	-	-	1.2	-	7.8	-	25.9	0.2	58.5
8.5 Carcinoma of genitourinary tract	0.2	0.7	0.7	2.7	1.9	10.1	4.3	20.9	9.3	32.8
8.5.1 Carcinoma of kidney	-	0.2	0.4	0.4	1.1	1.2	2.7	2.5	6.0	3.9
8.5.2 Carcinoma of bladder	-	-	0.3	-	0.7	0.3	1.3	0.4	2.0	0.9
8.5.3 Carcinoma of gonads	-	0.3	-	0.7	-	1.3	-	2.5	-	4.3
8.5.4 Carcinoma of cervix and uterus	-	-	-	1.5	-	7.1	-	14.8	-	22.7
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	-	-	-	0.2	0.3	0.7	1.2	1.1
8.6 Carcinoma of gastrointestinal tract	0.6	0.6	1.6	1.4	3.4	3.1	7.4	6.7	14.2	12.9
8.6.1 Carcinoma of colon and rectum	0.3	0.3	1.1	0.9	2.3	2.2	5.2	4.5	9.2	9.1
8.6.2 Carcinoma of stomach	-	-	0.1	0.2	0.4	0.4	1.0	1.0	1.7	1.3
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.2	-	0.1	0.2	0.3	0.2	0.3	0.3	0.6	0.5
8.6.4 Carcinoma of pancreas	-	-	-	-	0.2	0.2	0.3	0.5	1.0	0.9
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	-	-	0.3	0.2	0.6	0.3	1.6	1.0
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	0.2	0.3	0.4	0.4	0.6	0.7	0.9	1.2
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	-
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.2	0.2	0.3	0.4	0.6	0.6	0.9	1.1
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	0.3	0.4	0.3	0.4	0.6	0.8	1.0	1.3	1.6	2.3
9.1 Other pediatric and embryonal tumors, NOS	0.1	-	-	-	-	-	-	-	-	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	-	-	-	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.2 Other specified neoplasms, NOS	0.1	0.2	0.3	0.3	0.5	0.8	1.0	1.2	1.5	2.2
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	-	-	0.1	-	-	-	0.3
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	0.2	-	0.3	-	0.5	0.2	0.9	0.7
9.2.4 Other specified neoplasms, NOS ^c	-	-	-	0.2	0.1	0.5	0.3	0.7	0.4	1.3
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.2	0.3	0.2	0.4	0.3	0.7	0.6	1.0

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.6
Age-Specific SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
Black, 2007-2011

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
All Sites Combined	14.5	13.4	21.1	23.7	33.2	49.9	48.6	95.3	75.6	152.7
1. LEUKEMIAS	2.1	1.8	1.9	1.5	2.7	1.9	3.1	2.5	4.4	3.1
1.1 Acute lymphoid leukemia	1.3	0.8	-	-	-	-	-	-	-	-
1.2 Acute myeloid leukemia	-	0.8	-	0.9	1.1	1.1	1.2	1.3	1.6	1.5
1.3 Chronic myeloid leukemia	-	-	-	-	-	-	1.1	-	1.4	1.0
1.4 Other and unspecified leukemias	-	-	-	-	-	-	-	-	1.0	-
2. LYMPHOMAS	3.8	3.4	7.2	5.4	10.4	7.5	12.7	8.7	14.3	9.7
2.1 Non-Hodgkin Lymphoma	1.9	1.2	3.5	1.9	5.7	3.4	8.2	5.0	10.8	6.8
2.2 Hodgkin Lymphoma	1.9	2.2	3.7	3.5	4.8	4.1	4.5	3.8	3.6	2.9
3. CNS, INTRACRANIAL, INTRASPINAL	1.7	1.4	1.7	1.4	1.3	2.0	2.5	1.8	2.1	2.4
3.1 Astrocytoma	0.8	0.9	0.8	-	-	1.0	1.4	-	1.1	1.3
3.1.1 Specified low-grade astrocytic tumors	-	-	-	-	-	-	-	-	-	-
3.1.2 Glioblastoma and anaplastic astrocytoma	-	-	-	-	-	-	-	-	-	-
3.1.3 Astrocytoma, NOS	-	-	-	-	-	-	-	-	-	-
3.2 Other glioma	-	-	-	-	-	-	-	-	-	-
3.3 Ependymoma	-	-	-	-	-	-	-	-	-	-
3.4 Medulloblastoma and other PNET	-	-	-	-	-	-	-	-	-	-
3.4.1 Medulloblastoma	-	-	-	-	-	-	-	-	-	-
3.4.2 Supratentorial PNET	-	-	-	-	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	1.6	0.9	0.9	1.0	-	-	-	-	0.9	-
4.1 Osteosarcoma	1.1	0.7	-	-	-	-	-	-	-	-
4.2 Chondrosarcoma	-	-	-	-	-	-	-	-	-	-
4.3 Ewing tumor	-	-	-	-	-	-	-	-	-	-
4.4 Other specified and unspecified bone tumors	-	-	-	-	-	-	-	-	-	-
5. SOFT TISSUE SARCOMAS	1.5	1.2	4.3	2.4	6.5	2.8	7.5	4.8	9.2	4.9
5.1 Fibromatous neoplasms	-	-	-	0.7	1.1	-	1.4	1.6	2.2	1.7
5.2 Rhabdomyosarcoma	-	-	-	-	-	-	-	-	-	-
5.3 Other specified soft tissue sarcoma	0.7	-	3.6	1.4	5.2	2.0	5.9	3.1	6.8	3.2
5.3.1 Specified soft tissue sarcoma	-	-	3.1	1.0	4.7	1.7	5.4	2.7	6.2	2.7
5.3.1.1 Specified (excluding Kaposi sarcoma)	-	-	1.2	0.9	1.0	1.5	1.3	2.3	1.8	2.6
5.3.1.2 Kaposi sarcoma	-	-	2.0	-	3.7	-	4.0	-	4.4	-
5.3.2 Unspecified soft tissue sarcoma	-	-	-	-	-	-	-	-	-	-
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	0.9	0.9	1.7	1.3	2.4	1.3	3.5	-	2.7	-
6.1 Germ cell and trophoblastic neoplasms of gonads	-	-	1.6	-	2.4	-	3.1	-	2.5	-
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	-	-	-	-	-	-	-	-	-	-
6.2.1 Intracranial sites	-	-	-	-	-	-	-	-	-	-
6.2.2 Other nongonadal sites	-	-	-	-	-	-	-	-	-	-

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.6 - continued
 Age-Specific SEER Incidence^a, by Age Group and Sex
 By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
 Black, 2007-2011

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	-	-	-	-	-	-	-	-	-	-
7.1 Melanoma	-	-	-	-	-	-	-	-	-	-
7.2 Skin carcinomas	-	-	-	-	-	-	-	-	-	-
8. CARCINOMAS (excluding skin)	2.3	3.1	3.1	10.0	8.5	32.7	16.5	72.4	38.1	125.4
8.1 Thyroid carcinoma	-	1.3	-	2.9	1.2	6.1	1.6	11.5	2.1	14.4
8.2 Other carcinoma of head and neck	0.7	-	-	-	1.2	1.2	1.2	1.6	4.0	2.7
8.2.1 Nasopharyngeal carcinoma	-	-	-	-	-	-	-	-	-	-
8.2.2 Other sites in lip, oral cavity and pharynx	-	-	-	-	-	0.9	-	1.3	2.2	2.3
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	-	-	-	-	-	-	1.0	-
8.3 Carcinoma of trachea, bronchus, and lung	-	-	-	-	-	-	1.4	1.1	2.9	2.3
8.4 Carcinoma of breast	-	-	-	1.9	-	12.0	-	33.9	-	66.4
8.5 Carcinoma of genitourinary tract	-	-	0.8	2.9	1.6	8.5	4.6	15.9	11.4	22.8
8.5.1 Carcinoma of kidney	-	-	-	-	1.4	1.5	3.7	1.9	6.6	3.9
8.5.2 Carcinoma of bladder	-	-	-	-	-	-	-	-	1.4	-
8.5.3 Carcinoma of gonads	-	-	-	-	-	1.1	-	1.6	-	2.6
8.5.4 Carcinoma of cervix and uterus	-	-	-	1.7	-	5.4	-	11.5	-	14.8
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	-	-	-	-	-	-	3.3	1.0
8.6 Carcinoma of gastrointestinal tract	-	0.7	1.4	1.3	3.3	3.6	6.7	7.5	16.1	15.0
8.6.1 Carcinoma of colon and rectum	-	-	0.9	-	2.2	2.4	4.2	4.5	10.5	9.8
8.6.2 Carcinoma of stomach	-	-	-	-	-	-	-	1.0	1.9	1.7
8.6.3 Carcinoma of liver and intrahepatic bile ducts	-	-	-	-	-	-	1.0	-	1.4	-
8.6.4 Carcinoma of pancreas	-	-	-	-	-	-	-	0.9	0.9	1.6
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	-	-	-	-	-	-	1.3	1.4
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	-	-	-	-	-	0.9	1.4	1.9
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	-
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	-	-	-	-	-	0.8	1.3	1.7
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	-	0.7	-	-	-	-	1.1	2.8	2.6	3.3
9.1 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	-	-	-	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.2 Other specified neoplasms, NOS	-	-	-	-	-	-	-	2.7	2.6	3.2
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	-	-	-	-	-	-	-
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	-	-	-	-	-	-	1.8	1.2
9.2.4 Other specified neoplasms, NOS ^c	-	-	-	-	-	-	-	1.3	-	1.4
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	-	-	-	-	-	-	-	1.6

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.7

Age-Adjusted SEER Incidence^a, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
All Races, Ages 15-19

Both Sexes	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	13,904	20.4	0.6*	4,345	22.1	0.6*
1. Leukemias	1,657	2.4	0.8*	548	2.8	0.8*
2. Lymphomas	3,460	5.1	0.1	1,004	5.1	0.1
3. CNS, intracranial, intraspinal	1,339	2.0	0.2	397	2.0	0.2
4. Osseous & chondromatous neoplasms	1,082	1.6	0.6	336	1.7	0.6
5. Soft tissue sarcomas	1,021	1.5	0.4	310	1.6	0.4
6. Germ cell and trophoblastic neoplasms	1,691	2.5	0.9*	535	2.7	0.9*
7. Melanoma and skin carcinomas	1,031	1.5	0.9*	338	1.7	0.9*
8. Carcinomas (excluding skin)	2,356	3.5	1.7*	807	4.1	4.8*
9. Miscellaneous specified neoplasms, NOS	212	0.3	-0.1	66	0.3	-0.1
10. Unspecified malignant neoplasms	55	0.1	-	-	-	-

Males	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	7,309	21.0	0.6*	2,319	22.9	0.6*
1. Leukemias	986	2.8	0.4	320	3.2	0.4
2. Lymphomas	1,850	5.3	0.1	556	5.5	0.1
3. CNS, intracranial, intraspinal	776	2.2	0.2	229	2.3	0.2
4. Osseous & chondromatous neoplasms	706	2.0	0.8*	214	2.1	0.8*
5. Soft tissue sarcomas	538	1.5	0.3	163	1.6	0.3
6. Germ cell and trophoblastic neoplasms	1,237	3.6	1.2*	415	4.1	1.2*
7. Melanoma and skin carcinomas	410	1.2	1.1*	138	1.4	1.1*
8. Carcinomas (excluding skin)	685	2.0	1.5*	252	2.5	1.5*
9. Miscellaneous specified neoplasms, NOS	96	0.3	-	30	0.3	-
10. Unspecified malignant neoplasms	25	0.1	-	-	-	-

Females	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	6,595	19.8	0.5*	2,026	21.1	0.5*
1. Leukemias	671	2.0	1.4*	228	2.4	1.4*
2. Lymphomas	1,610	4.8	0.0	448	4.7	0.0
3. CNS, intracranial, intraspinal	563	1.7	0.1	168	1.8	0.1
4. Osseous & chondromatous neoplasms	376	1.1	0.3	122	1.3	0.3
5. Soft tissue sarcomas	483	1.5	0.4	147	1.5	0.4
6. Germ cell and trophoblastic neoplasms	454	1.4	0.0	120	1.3	0.0
7. Melanoma and skin carcinomas	621	1.9	0.6	200	2.1	0.6
8. Carcinomas (excluding skin)	1,671	5.0	1.7*	555	5.8	5.8*
9. Miscellaneous specified neoplasms, NOS	116	0.3	-	36	0.4	-
10. Unspecified malignant neoplasms	30	0.1	-	-	-	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).

Table 32.8

Age-Adjusted SEER Incidence^a, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
All Races, Ages 20-24

Both Sexes	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	23,710	34.1	0.8*	7,330	37.9	0.8*
1. Leukemias	1,529	2.2	0.9*	467	2.4	0.9*
2. Lymphomas	4,985	7.2	0.8*	1,497	7.7	-0.1
3. CNS, intracranial, intraspinal	1,572	2.3	0.7*	482	2.5	0.7*
4. Osseous & chondromatous neoplasms	635	0.9	1.3*	208	1.1	1.3*
5. Soft tissue sarcomas	1,461	2.1	1.0	386	2.0	-1.1*
6. Germ cell and trophoblastic neoplasms	3,696	5.3	0.8*	1,160	6.0	0.8*
7. Melanoma and skin carcinomas	2,989	4.3	1.2*	975	5.0	1.2*
8. Carcinomas (excluding skin)	6,465	9.3	0.4	2,042	10.5	1.4*
9. Miscellaneous specified neoplasms, NOS	237	0.3	1.3*	81	0.4	1.3*
10. Unspecified malignant neoplasms	141	0.2	-0.2	32	0.2	-0.2

Males	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	11,655	33.1	0.5*	3,481	35.1	0.5*
1. Leukemias	882	2.5	0.6	260	2.6	0.6
2. Lymphomas	2,679	7.6	0.4*	791	8.0	0.4*
3. CNS, intracranial, intraspinal	884	2.5	0.2	244	2.5	0.2
4. Osseous & chondromatous neoplasms	369	1.0	0.9	120	1.2	0.9
5. Soft tissue sarcomas	864	2.5	0.5	218	2.2	-2.6*
6. Germ cell and trophoblastic neoplasms	3,303	9.4	0.8*	1,044	10.5	0.8*
7. Melanoma and skin carcinomas	1,025	2.9	0.2	294	3.0	0.2
8. Carcinomas (excluding skin)	1,504	4.3	0.4	466	4.7	0.4
9. Miscellaneous specified neoplasms, NOS	91	0.3	-	31	0.3	-
10. Unspecified malignant neoplasms	54	0.2	-	-	-	-

Females	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	12,055	35.2	1.0*	3,849	40.7	1.0*
1. Leukemias	647	1.9	0.2	207	2.2	-0.2
2. Lymphomas	2,306	6.7	1.1*	706	7.5	-0.2
3. CNS, intracranial, intraspinal	688	2.0	1.4*	238	2.5	1.4*
4. Osseous & chondromatous neoplasms	266	0.8	1.7*	88	0.9	1.7*
5. Soft tissue sarcomas	597	1.7	0.8*	168	1.8	0.8*
6. Germ cell and trophoblastic neoplasms	393	1.1	0.3	116	1.2	0.3
7. Melanoma and skin carcinomas	1,964	5.7	1.7*	681	7.2	1.7*
8. Carcinomas (excluding skin)	4,961	14.5	0.5	1,576	16.7	1.5*
9. Miscellaneous specified neoplasms, NOS	146	0.4	1.4*	50	0.5	1.4*
10. Unspecified malignant neoplasms	87	0.3	-	19	0.2	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).

Table 32.9

Age-Adjusted SEER Incidence^a, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
All Races, Ages 25-29

Both Sexes	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	40,450	55.4	0.8*	11,944	61.0	1.2*
1. Leukemias	1,732	2.4	0.7*	521	2.7	0.7*
2. Lymphomas	6,074	8.3	0.7	1,661	8.5	0.7
3. CNS, intracranial, intraspinal	2,079	2.8	0.8*	614	3.1	0.8*
4. Osseous & chondromatous neoplasms	501	0.7	1.3*	155	0.8	1.3*
5. Soft tissue sarcomas	3,041	4.2	1.7	584	3.0	1.0
6. Germ cell and trophoblastic neoplasms	5,144	7.0	1.4*	1,579	8.1	2.1*
7. Melanoma and skin carcinomas	5,567	7.6	1.1*	1,773	9.1	1.1*
8. Carcinomas (excluding skin)	15,738	21.5	0.5*	4,876	24.9	1.4*
9. Miscellaneous specified neoplasms, NOS	379	0.5	1.8*	136	0.7	1.8*
10. Unspecified malignant neoplasms	195	0.3	-	45	0.2	-

Males	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	18,294	49.8	0.9*	5,220	53.0	1.5*
1. Leukemias	1,006	2.7	0.1	297	3.0	1.5*
2. Lymphomas	3,457	9.4	0.7	893	9.1	1.1
3. CNS, intracranial, intraspinal	1,138	3.1	0.9*	344	3.5	0.9*
4. Osseous & chondromatous neoplasms	289	0.8	0.6	78	0.8	0.6
5. Soft tissue sarcomas	2,232	6.1	1.9	386	3.9	0.0
6. Germ cell and trophoblastic neoplasms	4,750	12.9	1.7*	1,487	15.1	2.4*
7. Melanoma and skin carcinomas	1,987	5.4	0.3	564	5.7	0.3
8. Carcinomas (excluding skin)	3,201	8.7	0.3	1,085	11.0	1.9*
9. Miscellaneous specified neoplasms, NOS	149	0.4	-	61	0.6	-
10. Unspecified malignant neoplasms	85	0.2	-	25	0.3	-

Females	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	22,156	60.9	0.6*	6,724	69.2	1.0*
1. Leukemias	726	2.0	1.1*	224	2.3	1.1*
2. Lymphomas	2,617	7.2	0.8*	768	7.9	0.8*
3. CNS, intracranial, intraspinal	941	2.6	0.7	270	2.8	0.7
4. Osseous & chondromatous neoplasms	212	0.6	1.8*	77	0.8	1.8*
5. Soft tissue sarcomas	809	2.2	0.7	198	2.0	-1.2
6. Germ cell and trophoblastic neoplasms	394	1.1	-1.1*	92	0.9	-1.1*
7. Melanoma and skin carcinomas	3,580	9.8	1.6*	1,209	12.4	1.6*
8. Carcinomas (excluding skin)	12,537	34.5	0.4	3,791	39.0	1.2*
9. Miscellaneous specified neoplasms, NOS	230	0.6	0.8	75	0.8	0.8
10. Unspecified malignant neoplasms	110	0.3	-	20	0.2	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).

Table 32.10

Age-Adjusted SEER Incidence^a, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
All Races, Ages 30-34

Both Sexes	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	62,104	85.1	0.9*	17,850	91.0	1.1*
1. Leukemias	2,066	2.8	0.5*	609	3.1	0.5*
2. Lymphomas	6,826	9.4	1.6*	1,872	9.5	1.0
3. CNS, intracranial, intraspinal	2,458	3.4	0.4	700	3.6	0.4
4. Osseous & chondromatous neoplasms	462	0.6	0.6	134	0.7	0.6
5. Soft tissue sarcomas	5,037	6.9	1.3	737	3.8	-1.0
6. Germ cell and trophoblastic neoplasms	5,157	7.1	1.8*	1,580	8.1	0.5
7. Melanoma and skin carcinomas	7,922	10.9	1.6*	2,339	11.9	-0.1
8. Carcinomas (excluding skin)	31,200	42.8	0.6*	9,547	48.6	1.9*
9. Miscellaneous specified neoplasms, NOS	669	0.9	1.9*	238	1.2	1.9*
10. Unspecified malignant neoplasms	306	0.4	1.0	93	0.5	1.0

Males	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	25,804	70.7	0.9*	6,790	68.9	0.9*
1. Leukemias	1,205	3.3	0.8*	352	3.6	0.8*
2. Lymphomas	4,239	11.6	1.2	1,063	10.8	1.8
3. CNS, intracranial, intraspinal	1,430	3.9	0.2	403	4.1	0.2
4. Osseous & chondromatous neoplasms	254	0.7	0.4	69	0.7	0.4
5. Soft tissue sarcomas	4,059	11.1	1.2	457	4.6	-2.8*
6. Germ cell and trophoblastic neoplasms	4,821	13.2	1.8*	1,488	15.1	0.5
7. Melanoma and skin carcinomas	3,180	8.7	0.1	890	9.0	0.1
8. Carcinomas (excluding skin)	6,247	17.1	0.6*	1,935	19.6	2.5*
9. Miscellaneous specified neoplasms, NOS	262	0.7	2.4*	103	1.0	2.4*
10. Unspecified malignant neoplasms	107	0.3	-	30	0.3	-

Females	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	36,300	99.5	0.7*	11,060	113.2	1.5*
1. Leukemias	861	2.4	0.1	257	2.6	0.1
2. Lymphomas	2,587	7.1	1.3*	809	8.3	1.3*
3. CNS, intracranial, intraspinal	1,028	2.8	0.5	297	3.0	0.5
4. Osseous & chondromatous neoplasms	208	0.6	-	65	0.7	-
5. Soft tissue sarcomas	978	2.7	0.4	280	2.9	0.4
6. Germ cell and trophoblastic neoplasms	336	0.9	0.2	92	0.9	0.2
7. Melanoma and skin carcinomas	4,742	13.0	2.2*	1,449	14.8	1.0*
8. Carcinomas (excluding skin)	24,953	68.4	0.6*	7,612	77.9	1.7*
9. Miscellaneous specified neoplasms, NOS	407	1.1	1.7*	135	1.4	1.7*
10. Unspecified malignant neoplasms	199	0.5	-	63	0.6	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).

Table 32.11

Age-Adjusted SEER Incidence^a, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
All Races, Ages 35-39

Both Sexes	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	91,805	132.7	0.8*	27,810	138.0	0.9*
1. Leukemias	2,583	3.7	0.2	777	3.9	0.2
2. Lymphomas	7,726	11.2	1.6*	2,250	11.2	-1.4*
3. CNS, intracranial, intraspinal	2,736	4.0	-0.2	758	3.8	-0.2
4. Osseous & chondromatous neoplasms	456	0.7	1.4*	154	0.8	1.4*
5. Soft tissue sarcomas	5,935	8.6	1.1	1,025	5.1	-1.0
6. Germ cell and trophoblastic neoplasms	4,060	5.9	1.7*	1,311	6.5	0.3
7. Melanoma and skin carcinomas	10,003	14.5	1.6*	3,148	15.6	0.4*
8. Carcinomas (excluding skin)	56,654	81.9	0.5	17,877	88.7	1.4*
9. Miscellaneous specified neoplasms, NOS	1,178	1.7	1.1*	391	1.9	1.1*
10. Unspecified malignant neoplasms	474	0.7	-0.2	119	0.6	-0.2

Males	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	34,583	100.3	0.6	9,688	96.2	0.1
1. Leukemias	1,500	4.4	0.1	443	4.4	0.1
2. Lymphomas	5,044	14.6	1.8*	1,373	13.6	-0.7
3. CNS, intracranial, intraspinal	1,604	4.7	-0.1	439	4.4	-0.1
4. Osseous & chondromatous neoplasms	262	0.8	0.8	88	0.9	0.8
5. Soft tissue sarcomas	4,683	13.6	2.6	674	6.7	-1.3
6. Germ cell and trophoblastic neoplasms	3,851	11.2	1.8*	1,245	12.4	0.3
7. Melanoma and skin carcinomas	4,362	12.7	0.7	1,253	12.4	-0.6
8. Carcinomas (excluding skin)	12,614	36.6	0.2	3,977	39.5	1.4*
9. Miscellaneous specified neoplasms, NOS	471	1.4	0.5	153	1.5	0.5
10. Unspecified malignant neoplasms	192	0.6	-0.7	43	0.4	-0.7

Females	1975-2011			2002-2011		
	No.	Rate	AAPC ^c	No.	Rate	AAPC ^c
All Sites Combined	57,222	164.9	0.7*	18,122	179.7	1.2*
1. Leukemias	1,083	3.1	0.9	334	3.3	2.4*
2. Lymphomas	2,682	7.7	1.4*	877	8.7	1.4*
3. CNS, intracranial, intraspinal	1,132	3.3	-0.3	319	3.2	-0.3
4. Osseous & chondromatous neoplasms	194	0.6	-	66	0.7	-
5. Soft tissue sarcomas	1,252	3.6	-0.6	351	3.5	-0.6
6. Germ cell and trophoblastic neoplasms	209	0.6	-0.1	66	0.7	-0.1
7. Melanoma and skin carcinomas	5,641	16.3	2.1*	1,895	18.8	1.8*
8. Carcinomas (excluding skin)	44,040	126.9	0.6	13,900	137.8	1.4*
9. Miscellaneous specified neoplasms, NOS	707	2.0	1.4*	238	2.4	1.4*
10. Unspecified malignant neoplasms	282	0.8	-0.1	76	0.8	-0.1

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).

Table 32.12

SEER Incidence^a and U.S. Mortality^b Rate Comparison by Race/Ethnicity, 2007-2011
Ages 15-19

Males	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	22.6	24.9	14.5	16.5	22.2	3.4	3.5	3.3	3.2	4.0
Leukemia	3.6	4.0	2.1	3.1	5.2	1.0	1.0	0.8	0.7	1.4
Lymphoma	5.2	5.7	3.8	3.6	3.7	0.3	0.3	0.4	-	0.3
Hodgkin Lymphoma	3.0	3.4	1.9	2.2	2.2	0.1	0.1	-	-	-
Non-Hodgkin Lymphoma	2.2	2.3	1.9	1.4	1.6	0.3	0.2	0.3	-	0.2
Brain and Other Nervous System	2.3	2.5	1.7	1.5	1.7	0.5	0.6	0.4	0.5	0.5
Bones and Joints	1.7	1.8	1.6	1.3	1.8	0.6	0.6	0.4	-	0.7
Soft Tissue including Heart	1.2	1.2	1.0	-	1.1	0.3	0.3	0.4	-	0.3
Skin excluding Basal and Squamous	1.0	1.2	-	-	-	-	-	-	-	-
Respiratory System	0.4	0.4	0.7	-	0.7	0.1	0.1	-	-	-
Male Genital System	4.0	5.0	0.7	1.4	5.5	0.1	0.1	-	-	-
Digestive System	0.8	0.7	0.7	-	0.6	0.2	0.2	0.2	-	0.2

Females	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	20.6	22.5	13.4	15.7	18.6	2.5	2.5	2.5	1.9	2.7
Leukemia	2.7	3.0	1.8	1.7	3.5	0.7	0.7	0.6	0.7	1.1
Lymphoma	4.5	5.0	3.4	3.0	3.2	0.2	0.2	0.2	-	0.2
Hodgkin Lymphoma	3.3	3.7	2.2	2.3	2.2	0.1	0.1	-	-	-
Non-Hodgkin Lymphoma	1.2	1.3	1.2	-	1.0	0.1	0.1	-	-	-
Brain and Other Nervous System	1.9	2.0	1.3	1.1	1.4	0.4	0.4	0.5	-	0.3
Bones and Joints	0.9	0.9	0.9	-	0.8	0.4	0.4	0.3	-	0.4
Soft Tissue including Heart	1.1	1.2	0.8	-	1.1	0.3	0.3	0.2	-	0.2
Skin excluding Basal and Squamous	1.6	2.0	-	-	0.6	-	-	-	-	-
Respiratory System	0.2	0.3	-	-	-	-	-	-	-	-
Breast	0.2	-	-	-	-	-	-	-	-	-
Female Genital System	1.7	1.7	1.4	1.7	2.2	0.1	0.1	-	-	-
Digestive System	0.7	0.6	0.8	-	0.6	0.1	0.1	-	-	0.2

^a Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b US Mortality Files, National Center for Health Statistics, CDC.

^c Asian/Pacific Islander

^d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.13

SEER Incidence^a and U.S. Mortality^b Rate Comparison by Race/Ethnicity, 2007-2011
Ages 20-24

Males	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	34.6	38.8	21.1	19.4	31.9	5.5	5.7	5.6	4.4	5.8
Leukemia	3.0	3.2	1.9	2.5	3.9	1.2	1.3	1.1	1.0	1.8
Lymphoma	7.4	7.8	7.2	5.0	6.0	0.7	0.7	0.7	0.5	0.6
Hodgkin Lymphoma	4.3	4.6	3.7	3.0	3.0	0.2	0.2	0.2	-	0.2
Non-Hodgkin Lymphoma	3.1	3.2	3.5	2.0	3.0	0.4	0.4	0.5	-	0.4
Brain and Other Nervous System	2.3	2.6	1.6	1.3	1.7	0.7	0.7	0.5	-	0.5
Bones and Joints	1.0	1.2	0.7	-	0.9	0.7	0.7	0.6	-	0.7
Soft Tissue including Heart	1.3	1.3	1.7	-	1.0	0.4	0.4	0.6	-	0.4
Skin excluding Basal and Squamous	2.4	2.9	-	-	0.6	0.2	0.2	-	-	-
Respiratory System	0.8	0.9	-	-	0.9	0.2	0.2	0.2	-	-
Male Genital System	10.6	13.0	1.8	4.1	12.8	0.4	0.4	-	-	0.8
Digestive System	1.7	1.8	1.5	1.3	1.3	0.5	0.4	0.7	0.8	0.4

Females	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	37.1	40.6	23.7	25.2	28.2	3.6	3.6	4.3	2.6	3.6
Leukemia	2.2	2.3	1.5	1.8	2.8	0.8	0.8	0.8	-	1.1
Lymphoma	6.5	6.9	5.4	4.5	4.5	0.4	0.4	0.6	-	0.4
Hodgkin Lymphoma	4.6	5.1	3.5	2.6	3.0	0.2	0.2	0.3	-	0.2
Non-Hodgkin Lymphoma	1.9	1.8	1.9	1.9	1.5	0.2	0.2	0.3	-	0.2
Brain and Other Nervous System	2.1	2.3	1.5	1.8	1.4	0.4	0.5	0.4	-	0.4
Bones and Joints	0.8	0.7	0.9	-	0.4	0.3	0.3	0.2	-	0.3
Soft Tissue including Heart	1.3	1.2	1.6	1.4	1.1	0.3	0.3	0.5	-	0.2
Skin excluding Basal and Squamous	5.6	6.9	-	-	1.0	0.1	0.1	-	-	-
Respiratory System	0.4	0.5	-	-	0.4	0.1	0.1	-	-	-
Breast	1.5	1.4	2.0	1.6	1.2	0.1	0.1	0.2	-	-
Female Genital System	3.8	3.9	3.8	3.1	4.4	0.3	0.3	0.4	-	0.3
Digestive System	1.6	1.6	1.4	1.6	1.3	0.4	0.3	0.3	0.6	0.4

^a Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b US Mortality Files, National Center for Health Statistics, CDC.

^c Asian/Pacific Islander

^d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.14

SEER Incidence^a and U.S. Mortality^b Rate Comparison by Race/Ethnicity, 2007-2011
Ages 25-29

Males	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	48.7	53.4	33.2	26.6	38.7	7.1	7.1	7.9	5.0	6.2
Leukemia	3.3	3.5	2.7	2.1	3.6	1.3	1.3	1.3	1.0	1.5
Lymphoma	8.2	8.3	10.4	4.5	5.6	0.9	0.8	1.5	-	0.8
Hodgkin Lymphoma	4.1	4.3	4.8	2.3	2.2	0.3	0.3	0.4	-	0.2
Non-Hodgkin Lymphoma	4.1	4.0	5.7	2.2	3.5	0.6	0.5	1.1	-	0.6
Brain and Other Nervous System	3.1	3.6	1.3	2.0	2.2	0.9	1.0	0.6	0.5	0.5
Bones and Joints	0.7	0.8	-	-	0.6	0.4	0.4	0.3	-	0.2
Soft Tissue including Heart	1.5	1.5	1.9	1.0	1.4	0.5	0.5	0.6	-	0.4
Skin excluding Basal and Squamous	4.7	5.6	0.8	-	0.8	0.4	0.5	-	-	-
Respiratory System	1.2	1.2	1.0	1.1	1.1	0.3	0.3	0.4	-	0.3
Male Genital System	14.4	17.3	2.5	5.3	14.4	0.5	0.5	-	-	0.7
Digestive System	3.8	3.8	3.7	3.8	3.4	1.1	1.0	1.6	1.3	0.9

Females	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	66.0	71.1	49.9	43.9	53.1	6.1	6.0	7.7	4.4	5.4
Leukemia	2.4	2.6	1.9	2.1	2.7	0.8	0.9	0.7	0.8	1.1
Lymphoma	7.1	7.4	7.5	4.6	5.1	0.5	0.5	0.7	-	0.6
Hodgkin Lymphoma	4.1	4.6	4.1	2.0	2.8	0.2	0.2	0.2	-	0.3
Non-Hodgkin Lymphoma	2.9	2.8	3.4	2.6	2.3	0.3	0.3	0.5	-	0.3
Brain and Other Nervous System	2.4	2.6	2.0	1.3	1.9	0.6	0.6	0.5	-	0.3
Bones and Joints	0.6	0.7	-	-	0.5	0.2	0.2	-	-	-
Soft Tissue including Heart	1.3	1.3	1.6	0.9	1.2	0.3	0.3	0.5	-	0.2
Skin excluding Basal and Squamous	9.7	11.9	-	1.2	2.1	0.3	0.4	-	-	-
Respiratory System	0.9	0.8	1.1	1.1	0.5	0.2	0.2	-	-	0.2
Breast	8.6	8.2	12.1	6.9	6.8	0.7	0.6	1.4	-	0.6
Female Genital System	10.0	10.6	8.8	6.4	11.0	1.0	0.9	1.4	0.6	1.0
Digestive System	3.4	3.3	3.7	3.1	3.2	0.9	0.8	1.2	0.8	0.9

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).^b US Mortality Files, National Center for Health Statistics, CDC.^c Asian/Pacific Islander^d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.15

SEER Incidence^a and U.S. Mortality^b Rate Comparison by Race/Ethnicity, 2007-2011
Ages 30-34

Males	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	65.1	69.6	48.6	42.2	47.7	10.2	10.2	11.6	7.8	8.4
Leukemia	3.6	3.7	3.1	3.0	4.0	1.4	1.4	1.6	1.0	1.6
Lymphoma	9.8	9.8	12.7	5.5	6.7	1.1	1.1	1.6	-	0.9
Hodgkin Lymphoma	3.9	4.2	4.5	1.5	2.3	0.3	0.3	0.3	-	0.2
Non-Hodgkin Lymphoma	5.9	5.5	8.2	4.0	4.5	0.8	0.7	1.2	-	0.7
Brain and Other Nervous System	4.0	4.4	2.5	3.1	2.8	1.4	1.5	0.7	1.0	0.9
Bones and Joints	0.6	0.6	-	-	0.5	0.2	0.2	0.3	-	0.2
Soft Tissue including Heart	1.9	1.9	2.3	1.5	1.5	0.5	0.5	0.8	-	0.5
Skin excluding Basal and Squamous	8.0	9.5	1.4	1.2	2.0	0.7	0.8	-	-	-
Respiratory System	1.9	1.8	2.3	2.3	1.4	0.6	0.6	0.8	0.6	0.4
Male Genital System	13.8	16.5	3.6	4.7	11.5	0.4	0.5	-	-	0.6
Digestive System	7.9	7.9	7.0	8.3	7.5	2.4	2.3	3.2	2.6	2.2

Females	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	111.1	118.0	95.3	78.3	87.0	11.8	11.6	15.3	8.0	10.3
Leukemia	3.0	3.0	2.5	3.0	2.9	1.0	1.0	0.9	0.9	1.1
Lymphoma	7.4	7.6	8.7	4.9	5.6	0.7	0.6	1.0	-	0.6
Hodgkin Lymphoma	3.5	3.8	3.8	1.6	2.5	0.2	0.3	0.4	-	0.2
Non-Hodgkin Lymphoma	3.9	3.8	5.0	3.3	3.1	0.4	0.4	0.6	-	0.4
Brain and Other Nervous System	2.8	3.2	1.9	1.5	2.2	0.9	1.0	0.5	0.5	0.6
Bones and Joints	0.4	0.5	-	-	-	0.2	0.2	-	-	-
Soft Tissue including Heart	1.7	1.7	2.2	1.0	1.5	0.4	0.4	0.4	-	0.4
Skin excluding Basal and Squamous	12.0	14.8	1.8	1.2	2.8	0.5	0.6	-	-	-
Respiratory System	1.7	1.7	1.4	1.6	1.0	0.5	0.5	0.5	-	0.4
Breast	26.7	26.3	34.4	21.4	20.5	2.7	2.4	5.4	1.3	2.1
Female Genital System	18.8	19.8	16.7	13.1	20.3	2.1	2.1	2.7	1.1	2.1
Digestive System	7.3	7.2	8.0	6.3	6.3	1.9	1.8	2.4	1.8	2.1

^a Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b US Mortality Files, National Center for Health Statistics, CDC.

^c Asian/Pacific Islander

^d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.16

SEER Incidence^a and U.S. Mortality^b Rate Comparison by Race/Ethnicity, 2007-2011
Ages 35-39

Males	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	88.9	93.9	75.6	57.9	60.7	17.3	17.3	20.2	13.6	12.4
Leukemia	4.5	4.5	4.4	3.7	4.3	1.5	1.5	1.9	1.4	1.7
Lymphoma	11.7	12.1	14.3	5.3	8.9	1.5	1.4	2.3	0.7	1.3
Hodgkin Lymphoma	3.3	3.5	3.6	1.0	1.9	0.4	0.4	0.6	-	0.4
Non-Hodgkin Lymphoma	8.4	8.6	10.8	4.3	6.9	1.1	1.0	1.7	0.6	0.9
Brain and Other Nervous System	4.5	5.1	2.1	3.0	3.2	2.0	2.3	0.9	1.2	1.2
Bones and Joints	0.6	0.6	-	-	0.4	0.3	0.3	0.3	-	-
Soft Tissue including Heart	2.4	2.5	2.8	1.9	2.3	0.6	0.6	1.1	-	0.5
Skin excluding Basal and Squamous	11.1	13.3	2.0	1.4	2.5	1.0	1.2	0.3	-	0.2
Respiratory System	3.9	3.9	4.4	3.5	2.7	1.8	1.8	1.7	2.0	0.9
Male Genital System	12.1	14.1	5.9	3.6	9.2	0.5	0.5	0.3	-	0.5
Digestive System	15.4	14.9	17.1	16.3	12.4	5.4	5.1	7.1	5.0	4.1

Females	Incidence					Mortality				
	All Races	White	Black	API ^c	Hispanic ^d	All Races	White	Black	API ^c	Hispanic ^d
All Malignant Cancers	176.8	184.9	152.7	139.7	138.0	23.0	22.2	32.0	15.2	17.7
Leukemia	3.6	3.8	3.1	3.1	4.1	1.2	1.2	1.2	1.0	1.4
Lymphoma	8.5	8.6	9.7	4.9	6.7	0.9	0.8	1.2	-	0.7
Hodgkin Lymphoma	2.6	2.8	2.9	-	1.6	0.2	0.3	0.3	-	-
Non-Hodgkin Lymphoma	5.9	5.8	6.8	4.3	5.1	0.6	0.6	0.9	-	0.5
Brain and Other Nervous System	2.8	3.0	2.4	2.0	2.3	1.2	1.3	0.8	0.9	0.7
Bones and Joints	0.5	0.5	-	-	-	0.1	0.1	-	-	-
Soft Tissue including Heart	1.8	1.8	2.2	1.1	1.7	0.5	0.5	0.7	-	0.5
Skin excluding Basal and Squamous	16.2	20.0	1.9	1.6	4.4	0.7	0.9	-	-	0.2
Respiratory System	3.4	3.6	2.8	3.3	2.3	1.6	1.6	1.6	1.5	0.8
Breast	59.5	59.2	67.5	52.8	44.5	6.8	6.1	12.3	3.8	4.8
Female Genital System	28.7	30.6	21.6	24.1	29.6	4.1	4.0	5.4	2.1	3.5
Digestive System	13.8	13.6	16.0	11.8	12.4	3.8	3.5	5.6	3.5	3.4

Rates are per 100,000.

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).^b US Mortality Files, National Center for Health Statistics, CDC.^c Asian/Pacific Islander^d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.17

SEER Incidence^a and U.S. Mortality^b Rates and Trends for the Top 5 Cancer Sites^c by Age
All Races, Both Sexes, 1975-2011

	<u>Incidence</u>				<u>Mortality</u>			
	<u>1975-2011</u>		<u>2002-2011</u>		<u>1975-2011</u>		<u>2002-2011</u>	
	Rate	AAPC ^d	Rate	AAPC ^d	Rate	AAPC ^d	Rate	AAPC ^d
<u>Ages 15-19</u>								
All Malignant Cancers	20.4	0.6*	22.1	0.6*	4.1	-2.0*	3.1	-2.4*
Hodgkin Lymphoma	3.5	-0.6*	3.1	-0.6*	0.2	-4.8*	0.1	-4.8*
Brain and Other Nervous System	2.0	0.1	2.0	0.1	0.6	-1.2*	0.5	-1.2*
Thyroid	1.8	2.5*	2.3	6.7*	0.0	-	-	-
Non-Hodgkin Lymphoma	1.6	1.5*	2.0	1.5*	0.3	-3.0*	0.2	-3.0*
Testis	1.6	1.4*	1.9	1.4*	0.1	-5.8*	0.0	-3.6*
<u>Ages 20-24</u>								
All Malignant Cancers	34.1	0.8*	37.9	0.8*	5.6	-1.4*	4.7	-1.1*
Hodgkin Lymphoma	5.0	0.3	5.0	-0.6	0.4	-4.1*	0.2	-4.4*
Testis	4.5	1.0*	5.1	1.0*	0.3	-3.3*	0.2	2.1
Thyroid	4.2	1.8*	5.2	1.8*	0.0	-	0.0	-
Melanoma of the Skin	4.2	1.2*	4.9	1.2*	0.2	-2.9*	0.1	-1.7*
Brain and Other Nervous System	2.3	0.7*	2.5	0.7*	0.6	-0.8*	0.5	-0.8*
<u>Ages 25-29</u>								
All Malignant Cancers	55.4	0.8*	61.0	1.2*	8.4	-1.5*	6.7	-1.5*
Melanoma of the Skin	7.4	1.2*	8.9	1.2*	0.5	-2.9*	0.3	-2.9*
Thyroid	6.8	2.0*	9.9	4.0*	0.0	-	0.0	-
Testis	6.3	1.2*	7.4	1.2*	0.3	-3.1*	0.2	0.6
Hodgkin Lymphoma	4.8	0.0	4.7	0.0	0.6	-4.2*	0.3	-4.2*
Breast	4.1	0.0	4.2	0.0	0.5	-2.3*	0.3	-2.3*
<u>Ages 30-34</u>								
All Malignant Cancers	85.1	0.9*	91.0	1.1*	14.6	-1.5*	11.5	-1.5*
Breast	13.3	0.0	13.4	0.0	2.1	-2.1*	1.5	-2.7*
Melanoma of the Skin	10.5	1.6*	11.6	0.0	0.9	-2.0*	0.6	-0.9
Thyroid	8.7	2.5*	13.5	5.1*	0.0	-1.5*	0.0	-1.5*
Testis	6.5	2.0*	7.4	0.5	0.3	-3.1*	0.2	-1.5*
Cervix Uteri	5.8	-1.2*	4.9	-1.2*	0.9	-1.4*	0.7	-2.8*
<u>Ages 35-39</u>								
All Malignant Cancers	132.7	0.8*	138.0	0.9*	27.2	-1.5*	21.2	-2.0*
Breast	31.6	0.4	31.6	0.4*	5.1	-1.8*	3.7	-2.9*
Melanoma of the Skin	14.0	1.6*	15.0	0.4*	1.3	-2.2*	0.9	-1.9
Thyroid	10.6	3.7*	17.0	5.9*	0.1	-0.4	0.1	-0.4
Non-Hodgkin Lymphoma	7.9	2.1*	7.9	-0.1	1.5	-1.5*	0.9	-3.9*
Cervix Uteri	7.2	-1.3*	6.1	-1.3*	1.5	-1.4*	1.2	-0.9

Rates are per 100,000.

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b US Mortality Files, National Center for Health Statistics, CDC.

^c Top 5 cancer sites selected based on 1975-2011 SEER 9 Incidence rates for the age group.

^d The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero ($p < .05$).

Table 32.18

SEER Incidence^a and U.S. Mortality^b Rates and Trends for the Top 5 Cancer Sites^c by Age
All Races, Males, 1975-2011

	<u>Incidence</u>				<u>Mortality</u>			
	<u>1975-2011</u>		<u>2002-2011</u>		<u>1975-2011</u>		<u>2002-2011</u>	
	Rate	AAPC ^d	Rate	AAPC ^d	Rate	AAPC ^d	Rate	AAPC ^d
<u>Ages 15-19</u>								
All Malignant Cancers	21.0	0.6*	22.9	0.6*	4.9	-2.1*	3.7	-2.5*
Hodgkin Lymphoma	3.3	-0.6*	3.2	-0.6*	0.2	-5.0*	0.1	-5.0*
Testis	3.1	1.4*	3.7	1.4*	0.2	-5.9*	0.1	-3.7*
Brain and Other Nervous System	2.3	0.2	2.3	0.2	0.7	-1.1*	0.6	-1.1*
Non-Hodgkin Lymphoma	2.0	1.3*	2.3	1.3*	0.5	-3.0*	0.3	-3.0*
Bones and Joints	1.9	0.4	1.9	0.4	0.7	-1.4*	0.6	-0.1
<u>Ages 20-24</u>								
All Malignant Cancers	33.1	0.5*	35.1	0.5*	6.6	-1.5*	5.5	-0.9*
Testis	8.8	0.9*	10.0	0.9*	0.5	-3.4*	0.3	2.1
Hodgkin Lymphoma	4.9	-0.4	4.7	-0.4	0.5	-4.2*	0.2	-4.2*
Melanoma of the Skin	2.8	0.2	2.8	0.2	0.2	-2.7*	0.2	-2.7*
Non-Hodgkin Lymphoma	2.7	1.8*	3.2	1.8*	0.7	-2.1*	0.5	-5.3*
Brain and Other Nervous System	2.6	0.2	2.5	0.2	0.7	-0.7*	0.6	-0.7*
<u>Ages 25-29</u>								
All Malignant Cancers	49.8	0.9*	53.0	1.5*	8.9	-1.6*	7.1	-1.6*
Testis	12.6	1.2*	14.7	1.2*	0.7	-3.2*	0.4	0.6
Melanoma of the Skin	5.3	0.3	5.6	0.3	0.6	-2.7*	0.4	-0.1
Hodgkin Lymphoma	5.0	-0.2	4.8	-0.2	0.7	-4.5*	0.3	-4.5*
Non-Hodgkin Lymphoma	4.4	1.6	4.3	1.9	1.0	-1.7*	0.6	-5.6*
Kaposi sarcoma	3.9	-	1.3	-	-	-	-	-
<u>Ages 30-34</u>								
All Malignant Cancers	70.7	0.9*	68.9	0.9*	13.6	-1.5*	10.5	-1.2*
Testis	12.9	1.9*	14.8	0.5	0.6	-3.2*	0.4	-1.5*
Kaposi sarcoma	8.5	-	2.0	-	-	-	-	-
Melanoma of the Skin	8.4	0.2	8.8	0.2	1.1	-2.3*	0.7	-2.2*
Non-Hodgkin Lymphoma	7.3	1.4	6.3	0.7	1.4	-1.3	0.8	-3.5*
Hodgkin Lymphoma	4.3	0.2	4.5	0.2	0.7	-4.4*	0.4	-5.4*
<u>Ages 35-39</u>								
All Malignant Cancers	100.3	0.6	96.2	0.1	23.7	-1.5*	18.0	-1.3*
Melanoma of the Skin	12.2	0.7	11.9	-0.6*	1.6	-2.9*	1.0	-4.5*
Testis	11.0	1.9*	12.3	0.3	0.5	-2.8*	0.4	-1.2*
Non-Hodgkin Lymphoma	10.9	2.8*	10.0	0.0	2.1	-1.3*	1.2	-3.3
Kaposi sarcoma	10.3	-	3.0	-	-	-	-	-
Colon and Rectum	7.5	1.3*	9.1	1.3*	2.3	-0.3	2.2	1.6

Rates are per 100,000.

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b US Mortality Files, National Center for Health Statistics, CDC.

^c Top 5 cancer sites selected based on 1975-2011 rates for the age group.

^d The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero ($p < .05$).

Table 32.19

SEER Incidence^a and U.S. Mortality^b Rates and Trends for the Top 5 Cancer Sites^c by Age
All Races, Females, 1975-2011

	<u>Incidence</u>				<u>Mortality</u>			
	<u>1975-2011</u>		<u>2002-2011</u>		<u>1975-2011</u>		<u>2002-2011</u>	
	Rate	AAPC ^d	Rate	AAPC ^d	Rate	AAPC ^d	Rate	AAPC ^d
<u>Ages 15-19</u>								
All Malignant Cancers	19.8	0.5*	21.1	0.5*	3.4	-1.8*	2.6	-1.8*
Hodgkin Lymphoma	3.6	-0.6	3.1	-0.6	0.2	-4.3*	0.1	-4.3*
Thyroid	3.0	1.9*	3.8	1.9*	0.0	-	-	-
Melanoma of the Skin	1.8	0.7	2.0	0.7	0.1	-3.2*	0.0	-3.2*
Brain and Other Nervous System	1.7	0.0	1.7	0.0	0.5	-1.4*	0.4	-1.4*
Ovary	1.5	-0.2	1.4	-0.2	0.1	-4.4*	0.1	-4.4*
<u>Ages 20-24</u>								
All Malignant Cancers	35.2	1.0*	40.7	1.0*	4.5	-1.2*	3.8	-1.2*
Thyroid	7.2	2.1*	9.1	2.1*	0.0	-	-	-
Melanoma of the Skin	5.6	1.7*	7.0	1.7*	0.2	-3.2*	0.1	-3.2*
Hodgkin Lymphoma	5.0	0.8	5.3	-0.7	0.4	-3.2*	0.2	-3.2*
Cervix Uteri	2.1	-2.2*	1.4	-2.2*	0.2	-1.2*	0.1	-1.2*
Brain and Other Nervous System	2.0	1.4*	2.5	1.4*	0.5	-1.0*	0.4	-1.0*
<u>Ages 25-29</u>								
All Malignant Cancers	60.9	0.6*	69.2	1.0*	7.8	-1.4*	6.2	-1.4*
Thyroid	11.2	2.2*	16.8	4.4*	0.0	-	0.0	-
Melanoma of the Skin	9.6	1.7*	12.2	1.7*	0.4	-2.6*	0.3	-2.6*
Breast	8.2	0.0	8.4	0.0	1.0	-2.3*	0.7	-2.3*
Cervix Uteri	7.0	-2.2*	4.8	-3.3*	0.8	-1.6*	0.5	-1.6*
Hodgkin Lymphoma	4.6	0.2	4.7	0.2	0.5	-3.7*	0.2	-3.7*
<u>Ages 30-34</u>								
All Malignant Cancers	99.5	0.7*	113.2	1.5*	15.6	-1.5*	12.4	-1.9*
Breast	26.5	0.0	26.9	0.0	4.2	-2.0*	3.0	-2.6*
Thyroid	14.2	3.1*	22.6	5.3*	0.0	-	0.0	-
Melanoma of the Skin	12.7	2.3*	14.5	1.0*	0.7	-2.5*	0.5	-2.5*
Cervix Uteri	11.7	-1.2*	9.8	-1.2*	1.8	-1.4*	1.3	-2.7*
Hodgkin Lymphoma	3.7	0.9*	4.2	0.9*	0.5	-3.4*	0.3	-3.4*
<u>Ages 35-39</u>								
All Malignant Cancers	164.9	0.7*	179.7	1.2*	30.6	-1.5*	24.3	-2.1*
Breast	62.9	0.4	63.1	0.4*	10.1	-1.7*	7.4	-2.9*
Thyroid	16.6	4.1*	27.5	6.1*	0.1	-0.8	0.1	-0.8
Melanoma of the Skin	15.8	2.0*	18.2	0.7	1.0	-2.4*	0.7	-2.4*
Cervix Uteri	14.3	-1.3*	12.2	-1.3*	2.9	-1.6*	2.3	-2.3*
Corpus and Uterus, NOS	6.8	1.0*	8.4	3.3*	0.4	-1.3*	0.5	1.1*

Rates are per 100,000.

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b US Mortality Files, National Center for Health Statistics, CDC.

^c Top 5 cancer sites selected based on 1975-2011 rates for the age group.

^d The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2011.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).

Table 32.20

SEER^a 5-Year Relative Survival for the Top 5 Cancer Sites^b by Age
All Races, Both Sexes, 1975-2010

	5-year Relative Survival (Percent)					
	1975-2010	1975-1982	1983-1989	1990-1996	1997-2003	2004-2010
<u>Ages 15-19</u>						
All Malignant Cancers	77.6	68.9	76.2	78.9	80.2	84.3
Hodgkin Lymphoma	92.0	88.3	88.7	93.9	94.8	97.1
Brain and Other Nervous System	72.7	62.2	73.0	75.5	79.6	73.7
Thyroid	98.7	99.2	98.7	99.6	97.4	99.0
Non-Hodgkin Lymphoma	71.4	51.6	67.9	71.8	78.8	81.4
Testis	90.1	77.2	91.5	92.2	92.3	95.4
<u>Ages 20-24</u>						
All Malignant Cancers	80.5	74.7	78.0	80.6	84.0	85.8
Hodgkin Lymphoma	90.3	85.0	89.6	89.9	94.3	94.6
Testis	92.2	84.7	89.7	95.4	96.5	94.5
Thyroid	99.6	99.6	99.6	99.5	99.2	99.9
Melanoma of the Skin	92.5	85.8	90.4	94.4	95.6	96.4
Brain and Other Nervous System	66.3	59.0	59.8	70.2	66.0	76.2
<u>Ages 25-29</u>						
All Malignant Cancers	79.1	76.7	74.0	75.0	84.2	86.4
Melanoma of the Skin	93.1	88.1	91.0	94.3	95.6	96.0
Thyroid	99.7	99.7	99.4	99.8	99.7	99.5
Testis	94.9	88.1	94.7	96.2	96.9	97.4
Hodgkin Lymphoma	90.2	85.3	88.7	91.2	92.1	95.6
Breast	73.8	69.4	67.8	71.3	80.9	83.6
<u>Ages 30-34</u>						
All Malignant Cancers	75.3	73.4	68.6	69.4	81.6	85.0
Breast	76.8	70.0	71.9	77.0	81.8	85.3
Melanoma of the Skin	92.3	86.5	90.3	92.9	94.9	96.4
Thyroid	99.7	99.5	99.4	99.7	99.8	99.7
Testis	95.5	92.0	95.0	96.0	96.0	97.0
Cervix Uteri	84.9	84.3	82.6	84.7	88.5	84.6
<u>Ages 35-39</u>						
All Malignant Cancers	73.3	68.0	66.1	68.7	79.1	83.3
Breast	81.1	74.9	76.0	81.3	85.4	87.2
Melanoma of the Skin	92.1	87.4	89.9	92.1	94.2	95.3
Thyroid	99.4	99.0	99.1	99.3	99.2	99.8
Non-Hodgkin Lymphoma	62.5	65.8	52.8	48.2	70.6	81.1
Cervix Uteri	81.7	79.5	80.6	80.7	85.4	82.1

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Top 5 cancer sites selected based on 1975-2010 SEER 9 Incidence rates for the age group.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 32.21

SEER^a 5-Year Relative Survival for the Top 5 Cancer Sites^b by Age
All Races, Males, 1975-2010

	5-year Relative Survival (Percent)					
	1975-2010	1975-1982	1983-1989	1990-1996	1997-2003	2004-2010
<u>Ages 15-19</u>						
All Malignant Cancers	73.3	62.4	71.0	75.1	76.5	82.2
Hodgkin Lymphoma	91.0	86.8	87.2	92.8	94.8	96.8
Testis	90.1	77.2	91.5	92.2	92.3	95.4
Brain and Other Nervous System	69.6	58.3	66.9	74.0	77.6	72.7
Non-Hodgkin Lymphoma	69.0	45.6	67.6	74.0	74.5	78.2
Bones and Joints	58.2	42.0	53.2	63.3	64.2	69.7
<u>Ages 20-24</u>						
All Malignant Cancers	76.1	69.5	71.5	75.8	81.5	83.1
Testis	92.2	84.7	89.7	95.4	96.5	94.5
Hodgkin Lymphoma	88.4	83.5	85.8	88.1	94.6	93.3
Melanoma of the Skin	85.7	76.9	81.2	89.2	92.0	91.6
Non-Hodgkin Lymphoma	65.3	54.0	52.6	54.9	76.0	81.8
Brain and Other Nervous System	65.2	54.8	58.5	72.0	66.8	77.1
<u>Ages 25-29</u>						
All Malignant Cancers	72.7	71.2	65.3	66.3	80.7	83.0
Testis	94.9	88.1	94.7	96.2	96.9	97.4
Melanoma of the Skin	88.3	82.5	85.6	90.4	92.4	91.2
Hodgkin Lymphoma	88.0	84.0	85.1	87.2	92.2	94.1
Non-Hodgkin Lymphoma	57.3	57.3	48.1	41.6	73.2	76.8
Kaposi sarcoma	14.1	-	9.0	10.4	43.0	52.1
<u>Ages 30-34</u>						
All Malignant Cancers	66.8	68.6	57.2	56.8	77.3	81.8
Testis	95.5	92.0	95.0	96.0	96.0	97.0
Kaposi sarcoma	17.5	32.5	9.0	15.2	51.8	67.6
Melanoma of the Skin	87.8	79.2	85.0	90.0	91.4	94.1
Non-Hodgkin Lymphoma	53.5	69.8	44.0	34.3	66.8	78.8
Hodgkin Lymphoma	86.6	78.8	82.3	86.7	91.1	94.0
<u>Ages 35-39</u>						
All Malignant Cancers	62.9	59.6	52.2	54.8	72.5	78.0
Melanoma of the Skin	87.8	82.1	84.5	88.6	90.7	91.4
Testis	96.1	92.3	94.5	96.8	96.7	97.2
Non-Hodgkin Lymphoma	54.9	61.8	45.2	39.8	65.0	75.6
Kaposi sarcoma	18.3	-	6.9	14.7	54.8	69.5
Colon and Rectum	61.9	55.5	51.2	57.4	68.1	70.1

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Top 5 cancer sites selected based on 1975-2010 SEER 9 Incidence rates for the age group.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 32.22

SEER^a 5-Year Relative Survival for the Top 5 Cancer Sites^b by Age
All Races, Females, 1975-2010

	5-year Relative Survival (Percent)					
	1975-2010	1975-1982	1983-1989	1990-1996	1997-2003	2004-2010
<u>Ages 15-19</u>						
All Malignant Cancers	82.3	75.9	82.0	83.1	84.5	86.5
Hodgkin Lymphoma	92.9	89.7	90.2	94.9	94.7	97.0
Thyroid	99.2	99.0	100.0	99.5	97.7	99.6
Melanoma of the Skin	95.1	88.1	93.7	94.6	99.2	99.0
Brain and Other Nervous System	77.1	67.9	81.1	77.7	82.5	75.2
Ovary	87.8	78.5	89.9	89.2	94.6	88.4
<u>Ages 20-24</u>						
All Malignant Cancers	84.9	79.8	85.0	85.3	86.2	88.3
Thyroid	99.7	99.3	99.4	99.6	99.7	100.0
Melanoma of the Skin	96.1	91.5	96.0	96.9	97.2	98.4
Hodgkin Lymphoma	92.2	87.0	93.3	91.7	94.0	95.7
Cervix Uteri	88.0	89.1	90.1	86.1	88.0	84.4
Brain and Other Nervous System	67.7	65.2	61.7	67.4	64.8	75.6
<u>Ages 25-29</u>						
All Malignant Cancers	84.3	80.6	82.0	83.5	87.0	89.1
Thyroid	99.8	99.8	99.5	99.7	99.9	99.4
Melanoma of the Skin	95.8	91.9	94.4	96.6	97.4	98.2
Breast	73.8	69.4	67.6	71.5	80.9	83.9
Cervix Uteri	87.4	88.8	86.3	87.6	87.8	85.4
Hodgkin Lymphoma	92.7	86.8	92.6	95.5	91.8	97.0
<u>Ages 30-34</u>						
All Malignant Cancers	81.4	76.2	77.9	81.1	84.4	87.0
Breast	76.7	70.0	71.8	77.0	81.7	85.3
Thyroid	99.7	99.3	99.5	99.6	99.9	99.7
Melanoma of the Skin	95.3	92.1	94.1	94.8	97.0	97.7
Cervix Uteri	84.9	84.3	82.6	84.7	88.5	84.6
Hodgkin Lymphoma	91.0	85.1	88.9	91.3	93.1	96.0
<u>Ages 35-39</u>						
All Malignant Cancers	79.7	72.3	75.7	79.1	83.0	86.1
Breast	81.1	74.8	76.0	81.3	85.4	87.3
Thyroid	99.7	99.3	99.2	99.5	99.7	99.8
Melanoma of the Skin	95.6	92.3	94.6	95.0	96.8	97.9
Cervix Uteri	81.7	79.5	80.6	80.7	85.4	82.1
Corpus and Uterus, NOS	90.5	92.0	90.5	90.6	90.7	89.0

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

^b Top 5 cancer sites selected based on 1975-2010 SEER 9 Incidence rates for the age group.

- Statistic could not be calculated due to fewer than 25 cases during the time period.